Exact Mass: 267.1331

Exact Mass Matches: 267.1331

Found 96 metabolites which its exact mass value is equals to given mass value 267.1331, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Ergine

Ergoline-8-carboxamide, 9,10-didehydro-6-methyl-, (8.beta.)-

C16H17N3O (267.1372)


   

(-)-Caaverine

1-Hydroxy-2-methoxynoraporphine

C17H17NO2 (267.1259)


   
   

n-benzyl-3-oxo-n-phenylbutanamide

3-Oxo-N-phenyl-N-(phenylmethyl)butanamide

C17H17NO2 (267.1259)


   

6-Azaequilenin

6-Azaequilenin; 3-Hydroxy-6-azaestra-1,3,5(10),6,8-pentaen-17-one

C17H17NO2 (267.1259)


   

Voglibose

(1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

C10H21NO7 (267.1318)


Voglibose is only found in individuals that have used or taken this drug. Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix. [Wikipedia]Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level. (From Drug Therapy in Nursing, 2nd ed) Voglibose is an organic molecular entity. Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix. Voglibose is a valiolamine derivative and inhibitor of alpha-glucosidase with antihyperglycemic activity. Voglibose binds to and inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides and disaccharides into glucose and other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BF - Alpha glucosidase inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors C471 - Enzyme Inhibitor > C2846 - Glucosidase Inhibitor D004791 - Enzyme Inhibitors Voglibose is a derivative of valiolamine, which can inhibit α-glucosidase very well and can act on hyperglycemia.

   

Apomorphine

(9R)-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol

C17H17NO2 (267.1259)


A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. [PubChem] G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D005765 - Gastrointestinal Agents > D004639 - Emetics D002491 - Central Nervous System Agents

   

Voglibosa

5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

C10H21NO7 (267.1318)


   

Dihydrexidine

9-azatetracyclo[8.8.0.0^{2,7}.0^{13,18}]octadeca-2,4,6,13,15,17-hexaene-15,16-diol

C17H17NO2 (267.1259)


   

Lysergic acid amide

6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

C16H17N3O (267.1372)


   

Russian VX

2-methylpropyl {[2-(diethylamino)ethyl]sulfanyl}(methyl)phosphinate

C11H26NO2PS (267.1422)


   

S-(+)-apomorphine

10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,13,15-hexaene-3,4-diol

C17H17NO2 (267.1259)


   

O-Ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate

Methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester

C11H26NO2PS (267.1422)


VX nerve agent, also known as VX, belongs to the class of organic compounds known as trialkylamines. These are organic compounds containing a trialkylamine group, characterized by exactly three alkyl groups bonded to the amino nitrogen. Based on a literature review a significant number of articles have been published on VX nerve agent. This compound has been identified in human blood as reported by (PMID: 31557052 ). O-ethyl s-(2-diisopropylaminoethyl) methylphosphonothioate is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically O-Ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. VX is an extremely toxic synthetic chemical compound in the organophosphorus class, specifically, a thiophosphonate. In the class of nerve agents, it was developed for military use in chemical warfare after translation of earlier discoveries of organophosphate toxicity in pesticide research. In its pure form, VX is an oily, relatively non-volatile liquid that is amber-like in colour.[4] Because of its low volatility, VX persists in environments where it is dispersed.[5][6] VX, short for "venomous agent X",[7] is one of the best known of the V nerve agents and originated from pesticide development work at Imperial Chemical Industries (ICI). It was developed further at Porton Down in England during the early 1950s,[8] based on research first done by Gerhard Schrader, a chemist working for IG Farben in Germany during the 1930s.[citation needed] It is now one of a broader V-series of agents which are classified as nerve agents. VX has been allegedly used in warfare and has been used in several assassinations. The brother of North Korean leader Kim Jong Un, Kim Jong Nam, had the substance thrown in his face in Kuala Lumpur International Airport on the 13th February 2017 by two women. He died being rushed to hospital approximately 15 minutes later. The substance is extremely deadly; VX fatalities occur with exposure to tens of milligram quantities via inhalation or absorption through skin; VX is more potent than sarin, another nerve agent with a similar mechanism of action. On such exposure, these agents severely disrupt the body's signaling between the nervous and muscular systems, leading to a prolonged neuromuscular blockade, flaccid paralysis of all the muscles in the body including the diaphragm, and death by asphyxiation.[9] The danger of VX, in particular, lies in direct exposure to the chemical agent persisting where it was dispersed, and not through its evaporating and being distributed as a vapor; it is not considered a vapor hazard due to its relative non-volatility. VX is considered an area denial weapon due to these physical and biochemical characteristics.[10] As a chemical weapon, it is categorized as a weapon of mass destruction by the United Nations and is banned by the Chemical Weapons Convention of 1993,[11] where production and stockpiling of VX exceeding 100 grams (3.53 oz) per year is outlawed. The only exception is for "research, medical or pharmaceutical purposes outside a single small-scale facility in aggregate quantities not exceeding 10 kg (22 lb) per year per facility".[12]

   

Asimilobine

16-methoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-15-ol

C17H17NO2 (267.1259)


Asimilobine is a member of the class of compounds known as aporphines. Aporphines are quinoline alkaloids containing the dibenzo[de,g]quinoline ring system or a dehydrogenated derivative thereof. Asimilobine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Asimilobine can be found in cherimoya and custard apple, which makes asimilobine a potential biomarker for the consumption of these food products. Asimilobine is an inhibitor of dopamine biosynthesis, and a serotonergic receptor antagonist .

   

cinnamoyltyramine

N-[2-(4-Hydroxyphenyl)ethyl]-3-phenylprop-2-enimidate

C17H17NO2 (267.1259)


Cinnamoyltyramine is a member of the class of compounds known as cinnamic acid amides. Cinnamic acid amides are amides of cinnamic acids. Cinnamic acid is an aromatic compound containing a benzene and a carboxylic acid group forming 3-phenylprop-2-enoic acid. Cinnamoyltyramine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Cinnamoyltyramine can be found in a number of food items such as babassu palm, savoy cabbage, dill, and quinoa, which makes cinnamoyltyramine a potential biomarker for the consumption of these food products.

   

Erginine

Isolysergic acid amide

C16H17N3O (267.1372)


   

2-(5-tert-Butyl-2-hydroxyphenyl)benzotriazole

2-(5-tert-Butyl-2-hydroxyphenyl)benzotriazole

C16H17N3O (267.1372)


   

6,7-Dimethoxy-1-phenyl-3,4-dihydroisoquinoline

6,7-Dimethoxy-1-phenyl-3,4-dihydroisoquinoline

C17H17NO2 (267.1259)


   

Asimilobine

4H-DIBENZO(DE,G)QUINOLIN-2-OL, 5,6,6A,7-TETRAHYDRO-1-METHOXY-, (6AR)-

C17H17NO2 (267.1259)


R-(-)-asimilobine is an aporphine alkaloid. It has a role as a metabolite. Asimilobine is a natural product found in Meiogyne monosperma, Phoebe formosana, and other organisms with data available. A natural product found in Annona glabra.

   

N-Cinnamoyltryptamine

N-Cinnamoyltryptamine

C17H17NO2 (267.1259)


   

N-(2-phenylethyl)-4-hydroxycinnamamide|p-coumaroyl-beta-phenethylamine

N-(2-phenylethyl)-4-hydroxycinnamamide|p-coumaroyl-beta-phenethylamine

C17H17NO2 (267.1259)


   

2-(5-Benzyloxy-1H-indol-3-yl)-ethanol

2-(5-Benzyloxy-1H-indol-3-yl)-ethanol

C17H17NO2 (267.1259)


   

2,3-Epoxy-6,8-nonadiynoic acid phenethylamide|2-phenylethylamide-2,3-Epoxy-6,8-nonadiynoic acid|epoxy-nona-6,8-diynoic acid 2-phenylethylamide|nona-6,8-diyn-2,3-epoxy-1-oic acid phenylethylamine

2,3-Epoxy-6,8-nonadiynoic acid phenethylamide|2-phenylethylamide-2,3-Epoxy-6,8-nonadiynoic acid|epoxy-nona-6,8-diynoic acid 2-phenylethylamide|nona-6,8-diyn-2,3-epoxy-1-oic acid phenylethylamine

C17H17NO2 (267.1259)


   

(S)-N-trans-cinnamoyl-beta-hydroxy phenylethylamine

(S)-N-trans-cinnamoyl-beta-hydroxy phenylethylamine

C17H17NO2 (267.1259)


   

(2S,3R)-N-phenethyl-3-phenyloxirane-2-carboxamide

(2S,3R)-N-phenethyl-3-phenyloxirane-2-carboxamide

C17H17NO2 (267.1259)


   

10-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol

10-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol

C17H17NO2 (267.1259)


Based on the structure of 10-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol, we can speculate about its possible biological functions: Antioxidant Properties: The presence of hydroxyl (-OH) and methoxy (-OCH3) groups suggests that the compound might have antioxidant properties, capable of scavenging free radicals and protecting cells from oxidative stress. Anti-inflammatory Effects: Compounds with similar structures have been known to exhibit anti-inflammatory effects by inhibiting certain enzymes or pathways involved in the inflammatory response. Neuroprotective Activity: Given its structural similarity to certain alkaloids, it might have neuroprotective properties, potentially protecting neurons from damage caused by various neurotoxic agents. Antimicrobial Activity: The complex structure of the compound suggests that it might have antimicrobial properties, inhibiting the growth of certain bacteria or fungi. Central Nervous System (CNS) Activity: Compounds with similar structural features have been reported to have effects on the central nervous system, possibly acting as sedatives, anxiolytics, or antidepressants. Enzyme Inhibition: The compound might act as an inhibitor for certain enzymes, which could be relevant in various therapeutic contexts, such as cancer treatment or metabolic disorders. Ion Channel Modulation: It could potentially modulate ion channels, affecting cellular electrical activity, which could be relevant in conditions like epilepsy or cardiac arrhythmias.

   

Apomorphine

Apomorphine

C17H17NO2 (267.1259)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D005765 - Gastrointestinal Agents > D004639 - Emetics D002491 - Central Nervous System Agents CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2773; ORIGINAL_PRECURSOR_SCAN_NO 2770 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2742; ORIGINAL_PRECURSOR_SCAN_NO 2740 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2770; ORIGINAL_PRECURSOR_SCAN_NO 2767 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2761; ORIGINAL_PRECURSOR_SCAN_NO 2760 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2765; ORIGINAL_PRECURSOR_SCAN_NO 2764 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2768; ORIGINAL_PRECURSOR_SCAN_NO 2767 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5817; ORIGINAL_PRECURSOR_SCAN_NO 5813 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5827; ORIGINAL_PRECURSOR_SCAN_NO 5825 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5853; ORIGINAL_PRECURSOR_SCAN_NO 5851 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5859; ORIGINAL_PRECURSOR_SCAN_NO 5857 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5863; ORIGINAL_PRECURSOR_SCAN_NO 5861 CONFIDENCE standard compound; INTERNAL_ID 796; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5858; ORIGINAL_PRECURSOR_SCAN_NO 5856 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2542; CONFIDENCE confident structure

   

6,7-Dimethoxy-1-phenyl-3,4-dihydro-isoquinoline

"NCGC00160325-01!6,7-Dimethoxy-1-phenyl-3,4-dihydro-isoquinoline"

C17H17NO2 (267.1259)


   

(R)-1-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-ol

(R)-1-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-ol

C17H17NO2 (267.1259)


   

Voglibose

(1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

C10H21NO7 (267.1318)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BF - Alpha glucosidase inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors C471 - Enzyme Inhibitor > C2846 - Glucosidase Inhibitor D004791 - Enzyme Inhibitors Voglibose is a derivative of valiolamine, which can inhibit α-glucosidase very well and can act on hyperglycemia.

   

2-(2H-benzotriazol-2-yl)-4-tert-butylphenol

2-(2H-benzotriazol-2-yl)-4-tert-butylphenol

C16H17N3O (267.1372)


   

6-BENZYLOXY-7-METHOXY-3,4-DIHYDRO-ISOQUINOLINE

6-BENZYLOXY-7-METHOXY-3,4-DIHYDRO-ISOQUINOLINE

C17H17NO2 (267.1259)


   

2-Benzyl-1,2,3,4-tetrahydroisoquinoline-8-carboxylic acid

2-Benzyl-1,2,3,4-tetrahydroisoquinoline-8-carboxylic acid

C17H17NO2 (267.1259)


   

Methanone,[4-(4-morpholinyl)phenyl]phenyl-

Methanone,[4-(4-morpholinyl)phenyl]phenyl-

C17H17NO2 (267.1259)


   

1-[2-[4-(chloromethyl)phenoxy]ethyl]azepane

1-[2-[4-(chloromethyl)phenoxy]ethyl]azepane

C15H22ClNO (267.139)


   

4-ETHOXYBENZYLIDENE-4-ACETYLANILINE

4-ETHOXYBENZYLIDENE-4-ACETYLANILINE

C17H17NO2 (267.1259)


   

1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline

1-[(4-methoxyphenoxy)methyl]-3,4-dihydroisoquinoline

C17H17NO2 (267.1259)


   

benzyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate

benzyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate

C14H18FNO3 (267.1271)


   

(2-HYDROXY-[1,1-BIPHENYL]-3-YL)(PYRROLIDIN-1-YL)METHANONE

(2-HYDROXY-[1,1-BIPHENYL]-3-YL)(PYRROLIDIN-1-YL)METHANONE

C17H17NO2 (267.1259)


   

7-Benzyloxy-6-methoxy-3,4-dihydroisoquinoline

7-Benzyloxy-6-methoxy-3,4-dihydroisoquinoline

C17H17NO2 (267.1259)


   
   

tert-butyl 3-(3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate

tert-butyl 3-(3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate

C14H18FNO3 (267.1271)


   

(2E)-3-[4-(Dimethylamino)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one

(2E)-3-[4-(Dimethylamino)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one

C17H17NO2 (267.1259)


   

n-cinnamoyl-n-(2,3-xylyl)hydroxylamine

n-cinnamoyl-n-(2,3-xylyl)hydroxylamine

C17H17NO2 (267.1259)


   

BENZYL (3R)-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXYLATE

BENZYL (3R)-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXYLATE

C17H17NO2 (267.1259)


   

Ethyl 2-((diphenylmethylene)amino)acetate

Ethyl 2-((diphenylmethylene)amino)acetate

C17H17NO2 (267.1259)


   

vx.

O-Ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate

C11H26NO2PS (267.1422)


D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D009676 - Noxae > D011042 - Poisons > D002619 - Chemical Warfare Agents D004791 - Enzyme Inhibitors

   

N-(3-oxo-1,3-diphenylpropyl)acetamide

N-(3-oxo-1,3-diphenylpropyl)acetamide

C17H17NO2 (267.1259)


   

Dihydrexidine

5,6,6a,7,8,12b-Hexahydrobenzo[a]phenanthridine-10,11-diol

C17H17NO2 (267.1259)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

1-BENZYL-4-(4-FLUOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE

1-BENZYL-4-(4-FLUOROPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE

C18H18FN (267.1423)


   

1-BENZHYDRYLAZETANE-3-CARBOXYLIC ACID

1-BENZHYDRYLAZETANE-3-CARBOXYLIC ACID

C17H17NO2 (267.1259)


   

N-(1,1-DIMETHYL-2-OXO-2-PHENYL-ETHYL)-BENZAMIDE

N-(1,1-DIMETHYL-2-OXO-2-PHENYL-ETHYL)-BENZAMIDE

C17H17NO2 (267.1259)


   

2-[(benzyl-methyl-amino)methyl]cyclohexan-1-one

2-[(benzyl-methyl-amino)methyl]cyclohexan-1-one

C15H22ClNO (267.139)


   

N-ACETYL-O-AMINOAZOTOLUENE

N-ACETYL-O-AMINOAZOTOLUENE

C16H17N3O (267.1372)


   

tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate

tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate

C14H18FNO3 (267.1271)


   
   

4Cl-PVP Research Powder

4Cl-PVP Research Powder

C15H22ClNO (267.139)


   

2-Benzyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid

2-Benzyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid

C17H17NO2 (267.1259)


   

Aloisine A

4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol

C16H17N3O (267.1372)


   

7-(1-Pyrrolidinylmethyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one

7-(1-Pyrrolidinylmethyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one

C16H17N3O (267.1372)


   

METHYL 2-BENZYLISOINDOLINE-4-CARBOXYLATE

METHYL 2-BENZYLISOINDOLINE-4-CARBOXYLATE

C17H17NO2 (267.1259)


   

(S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLICACID BENZYL ESTER HYDROCHLORIDE

(S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLICACID BENZYL ESTER HYDROCHLORIDE

C17H17NO2 (267.1259)


   

3-benzyl-1-(benzyloxy)azetidin-2-one

3-benzyl-1-(benzyloxy)azetidin-2-one

C17H17NO2 (267.1259)


   

2-(6-phenylmethoxy-1H-indol-3-yl)ethanol

2-(6-phenylmethoxy-1H-indol-3-yl)ethanol

C17H17NO2 (267.1259)


   

L(+)-2-AMINO-6-(O,O-DIETHYLPHOSPHONO)HEXANOIC ACID

L(+)-2-AMINO-6-(O,O-DIETHYLPHOSPHONO)HEXANOIC ACID

C10H22NO5P (267.1236)


   

4-N-Boc-amino-3-methoxyphenylboronic acid

4-N-Boc-amino-3-methoxyphenylboronic acid

C12H18BNO5 (267.1278)


   

2-(5-phenylmethoxy-1H-indol-3-yl)ethanol

2-(5-phenylmethoxy-1H-indol-3-yl)ethanol

C17H17NO2 (267.1259)


   

(S)-2-AMINOBUT-3-EN-1-OL,BENZOATESALT

(S)-2-AMINOBUT-3-EN-1-OL,BENZOATESALT

C14H21NO2S (267.1293)


   

Benzyl 1,2,3,4-tetrahydro-2-quinolinecarboxylate

Benzyl 1,2,3,4-tetrahydro-2-quinolinecarboxylate

C17H17NO2 (267.1259)


   

N-cinnamoyltyramine

N-cinnamoyltyramine

C17H17NO2 (267.1259)


   
   

Cafaminol

Cafaminol

C11H17N5O3 (267.1331)


C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

   

3-(5-Methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propanone

3-(5-Methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol-3-yl)-1-propanone

C16H17N3O (267.1372)


   

Mesityl(piperidin-4-yl)methanone hydrochloride

Mesityl(piperidin-4-yl)methanone hydrochloride

C15H22ClNO (267.139)


   

3-(1-hydroxy-5,5-dimethyl-4-phenyl-2H-imidazol-2-yl)pyridine

3-(1-hydroxy-5,5-dimethyl-4-phenyl-2H-imidazol-2-yl)pyridine

C16H17N3O (267.1372)


   

(2E,3E)-4-[4-(benzyloxy)phenyl]-N-hydroxybut-3-en-2-imine

(2E,3E)-4-[4-(benzyloxy)phenyl]-N-hydroxybut-3-en-2-imine

C17H17NO2 (267.1259)


   

4-(Methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile

4-(Methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile

C16H17N3O (267.1372)


   

N-[(E)-1-Cyclopropylethylideneamino]-2-pyrrol-1-ylbenzamide

N-[(E)-1-Cyclopropylethylideneamino]-2-pyrrol-1-ylbenzamide

C16H17N3O (267.1372)


   

(S)-3-(indol-3-ylmethyl)-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazin-1-one

(S)-3-(indol-3-ylmethyl)-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazin-1-one

C16H17N3O (267.1372)


   

2-methoxy-N-[(1-methyl-2-benzimidazolyl)methyl]aniline

2-methoxy-N-[(1-methyl-2-benzimidazolyl)methyl]aniline

C16H17N3O (267.1372)


   

2-(3-Methylpentan-2-ylamino)-6-methylsulanylbenzoic acid

2-(3-Methylpentan-2-ylamino)-6-methylsulanylbenzoic acid

C14H21NO2S (267.1293)


   

N-Hydroxy-3,4-(methylenedioxy)amphetamine, TMS derivative

N-Hydroxy-3,4-(methylenedioxy)amphetamine, TMS derivative

C13H21NO3Si (267.1291)


   

4-Amino-5,7-dimethylflavanone

4-Amino-5,7-dimethylflavanone

C17H17NO2 (267.1259)


   

2-Butoxy-3-pyridinecarboxylic acid trimethylsilyl ester

2-Butoxy-3-pyridinecarboxylic acid trimethylsilyl ester

C13H21NO3Si (267.1291)


   

LYSERGAMIDE

LYSERGAMIDE

C16H17N3O (267.1372)


An ergoline alkaloid comprising ergoline lacking hydrogens at positions 9 and 10 and also having a methyl group attached to the piperidine nitrogen.

   

6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol

6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol

C17H17NO2 (267.1259)


   

N-trans-cinnamoyltyramine

N-trans-cinnamoyltyramine

C17H17NO2 (267.1259)


A member of the class of cinnamamides that is tyramine substituted by a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at the nitrogen atom. It is found in rice and exhibits an allelopathic effect to suppress the growth of weeds.

   

15-methoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol

15-methoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-16-ol

C17H17NO2 (267.1259)


   

(4s,7r)-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

(4s,7r)-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C16H17N3O (267.1372)


   

(2s,3r)-3-(hexa-3,5-diyn-1-yl)-n-(2-phenylethyl)oxirane-2-carboximidic acid

(2s,3r)-3-(hexa-3,5-diyn-1-yl)-n-(2-phenylethyl)oxirane-2-carboximidic acid

C17H17NO2 (267.1259)


   

(2s,3r)-3-phenyl-n-(2-phenylethyl)oxirane-2-carboximidic acid

(2s,3r)-3-phenyl-n-(2-phenylethyl)oxirane-2-carboximidic acid

C17H17NO2 (267.1259)


   

(2e)-n-[2-(4-hydroxyphenyl)ethyl]-3-phenylprop-2-enimidic acid

(2e)-n-[2-(4-hydroxyphenyl)ethyl]-3-phenylprop-2-enimidic acid

C17H17NO2 (267.1259)


   

3-(hexa-3,5-diyn-1-yl)-n-(2-phenylethyl)oxirane-2-carboximidic acid

3-(hexa-3,5-diyn-1-yl)-n-(2-phenylethyl)oxirane-2-carboximidic acid

C17H17NO2 (267.1259)


   

6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C16H17N3O (267.1372)


   

n-[2-(4-hydroxyphenyl)ethyl]-3-phenylprop-2-enimidic acid

n-[2-(4-hydroxyphenyl)ethyl]-3-phenylprop-2-enimidic acid

C17H17NO2 (267.1259)


   

4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(15),2(7),3,5,12(16),13-hexaene

4,5-dimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(15),2(7),3,5,12(16),13-hexaene

C17H17NO2 (267.1259)